GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » Short Percentage of Float

Lumosa Therapeutics Co (ROCO:6535) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Lumosa Therapeutics Co's Short Percentage of Float

For the Biotechnology subindustry, Lumosa Therapeutics Co's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumosa Therapeutics Co's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's Short Percentage of Float falls into.


;
;

Lumosa Therapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » Short Percentage of Float
Comparable Companies
ROCO:4743 TPE:6550 ROCO:4728 ROCO:4147 ROCO:6589 ROCO:6547 ROCO:6617 ROCO:6712 TPE:6541 ROCO:4162 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Website
https://www.lumosa.com.tw
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.

Lumosa Therapeutics Co Headlines

No Headlines